Platinum-resistant Ovarian Cancer - A Pipeline Analysis Report
- Published: Jun 2018
- Pages: 166
- SKU: IRTNTR22397
The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!
This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for platinum-resistant ovarian cancer including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.
Overview of the drug development pipeline for platinum-resistant ovarian cancer
Ovarian cancer is the most lethal gynecologic malignancy. It is formed in or on an ovary. This cancer can spread to the abdominal lining, lungs, and liver. It is difficult to detect ovarian cancer in the early stages, giving the asymptomatic nature of this indication. It reduces patients’ survival span, which is usually less than five years since the genesis of the tumor. Ovarian cancer can be classified in two types on the reaction to chemotherapy drugs. The types are platinum-sensitive and platinum-resistant ovarian cancer. As per the NIH, patients with ovarian cancer have less than 47% chances of surviving for more than five years. The prevalence of this disease in unevenly distributed while being more common in less developed countries compared to the advanced economies. About 58% of ovarian cancer cases are from less developed countries. The disease is also very common in older women. In 2015, 28% of all the new cases of ovarian cancer were in women aging above 75 years. Consequently, Technavio’s market research analysts suggest with the increase in instances of ovarian cancer, the drug development for platinum-resistant ovarian cancer has been promoted.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for the treatment of platinum-resistant recurrent ovarian cancer. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development for the drug development molecules for the treatment of ovarian cancer. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Eli Lilly
Therapeutic assessment of the drug development pipeline for platinum-resistant ovarian cancer by route of administration
The intravenous route of administration (ROA) involves the application of the drug directly into the veins, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for platinum-resistant ovarian cancer by therapy
- Combination therapy
According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for platinum-resistant ovarian cancer are being developed as combination therapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for platinum-resistant ovarian cancer?
- What are the companies that are currently involved in the development of drug development molecules for platinum-resistance ovarian cancer?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX
- List of abbreviations
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get your FREE sample now!
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Did you know?
Did you know?
Did you know?
Want to customize this report?
This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.